Savara Reports Wider Q1 Loss Amid MOLBREEVI Launch Preparations

Event summary

  • Savara reported a net loss of $37.3M for Q1 2026, up from $26.6M in Q1 2025, driven by increased R&D and G&A expenses.
  • R&D expenses rose 22.1% to $23.4M, primarily due to MOLBREEVI program costs and higher personnel expenses.
  • G&A expenses surged 68.4% to $15.6M, mainly from increased share-based compensation.
  • Company has $203M in cash and potential access to $150M in non-dilutive capital upon MOLBREEVI approval.
  • PDUFA action date for MOLBREEVI set for November 22, 2026.

The big picture

Savara's widening losses reflect the high costs of preparing for MOLBREEVI's potential approval and commercial launch. The company's focus on rare respiratory diseases positions it in a niche market with high unmet medical needs, but success hinges on navigating regulatory hurdles and demonstrating the drug's efficacy in autoimmune PAP. The upcoming PDUFA date represents a critical inflection point for the company's financial and operational trajectory.

What we're watching

Regulatory Approval
Whether MOLBREEVI receives FDA approval by the November 22 PDUFA date, unlocking $150M in non-dilutive capital.
Commercialization Readiness
The pace at which Savara can scale its commercial launch preparations for autoimmune PAP treatment.
Financial Sustainability
How long Savara's current cash position will last amid rising expenses and potential future funding needs.